1. Figure 5 Transferrin saturation, NTBI and bacterial growth in the serum of three stem cell transplantation patients, of whom one (A) did not receive apotransferrin and two (B,C) received repeated intravenous apotransferrin infusions at two different dose levels. Bacterial growth was monitored as in Fig. 3. Arrows indicate the apotransferrin infusions, closed and open arrows corresponding to doses of 100–115 mg kg⁻¹ and 26 mg kg⁻¹, respectively.
From: Erratum to “Apotransferrin administration prevents growth of Staphylococcus epidermidis in serum of stem cell transplant patients by binding of free iron” [FEMS Immunol. Med. Microbiol. 37 (2003) 45–51]
FEMS Immunol Med Microbiol. 2004;40(2): doi: /S (03)00347-X
FEMS Immunol Med Microbiol | © 2003 Federation of European Microbiological Societies.

2. Figure 4 Effect of a single intravenous administration of apotransferrin on transferrin saturation, NTBI and growth of S. epidermidis in the serum samples of three stem cell transplantation patients. Bacterial growth was measured as in Fig. 3. The arrow indicates the intravenous injection of 100 mg kg⁻¹ apotransferrin 3 days after the stem cell transplantation.
From: Erratum to “Apotransferrin administration prevents growth of Staphylococcus epidermidis in serum of stem cell transplant patients by binding of free iron” [FEMS Immunol. Med. Microbiol. 37 (2003) 45–51]
FEMS Immunol Med Microbiol. 2004;40(2): doi: /S (03)00347-X
FEMS Immunol Med Microbiol | © 2003 Federation of European Microbiological Societies.

3. Figure 3 Relation of bacterial growth measured as an increase in optical density (ΔOD) to transferrin saturation in the serum samples of the stem cell transplantation patients (n=132). The growth of an inoculum of 10³ cfu ml⁻¹ of strain was monitored as the increase in optical density during 24 h. The line indicates the detection limit.
From: Erratum to “Apotransferrin administration prevents growth of Staphylococcus epidermidis in serum of stem cell transplant patients by binding of free iron” [FEMS Immunol. Med. Microbiol. 37 (2003) 45–51]
FEMS Immunol Med Microbiol. 2004;40(2): doi: /S (03)00347-X
FEMS Immunol Med Microbiol | © 2003 Federation of European Microbiological Societies.

4. Figure 2 Effect of the initial bacterial count on the growth of S
Figure 2 Effect of the initial bacterial count on the growth of S. epidermidis in normal serum and in serum containing NTBI. A: Growth curves of different initial bacterial densities in normal serum (closed symbols) and in the same serum with added NTBI (open symbols). B: Viable counts at the beginning and after 24 h in the same sera. Growth of strain was monitored as described in Fig. 1. Bars indicate the mean and S.E.M. of repeated (n=4) experiments. The difference between the viable counts after 24 h in normal serum and in the same serum with NTBI was statistically significant at all starting cell densities (10³ cfu ml⁻¹P<0.0001, 10⁴ cfu ml⁻¹P<0.01 and 10⁵ cfu ml⁻¹P<0.05, Student's t-test).
From: Erratum to “Apotransferrin administration prevents growth of Staphylococcus epidermidis in serum of stem cell transplant patients by binding of free iron” [FEMS Immunol. Med. Microbiol. 37 (2003) 45–51]
FEMS Immunol Med Microbiol. 2004;40(2): doi: /S (03)00347-X
FEMS Immunol Med Microbiol | © 2003 Federation of European Microbiological Societies.

5. Figure 1 Effect of in vitro addition of iron and transferrin on growth of S. epidermidis in serum. An inoculum of 10³ cfu ml⁻¹ was added to buffered serum, growth was carried out at 37°C in a 5% CO₂ atmosphere and monitored by optical density. Viable counts determined after 24 h are shown beside the growth curves. A: Two clinical isolates, and 19435, and the ATCC strain were grown in normal serum (closed symbols) and in the same serum with added NTBI (open symbols). B: Growth of strain in a patient serum containing 0.4 µM NTBI and in the same serum after addition of 0.1 g l⁻¹ iron-free apotransferrin or 0.1 g l⁻¹ iron-saturated holotransferrin.
From: Erratum to “Apotransferrin administration prevents growth of Staphylococcus epidermidis in serum of stem cell transplant patients by binding of free iron” [FEMS Immunol. Med. Microbiol. 37 (2003) 45–51]
FEMS Immunol Med Microbiol. 2004;40(2): doi: /S (03)00347-X
FEMS Immunol Med Microbiol | © 2003 Federation of European Microbiological Societies.